{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:21:54Z","timestamp":1793467314101,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ebiom.2019.102625","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T19:12:53Z","timestamp":1579720373000},"page":"102625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"special_numbering":"C","title":["DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing"],"prefix":"10.1016","volume":"52","author":[{"given":"Patrick J.","family":"Engelberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida H.","family":"Hiemstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danita H.","family":"Schuurhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Meesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irati","family":"Beltran Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone C.","family":"Oostindie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Neijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward N.","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Jean","family":"Horbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Verploegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aran F.","family":"Labrijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Schuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.H.I","family":"Parren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther C.W.","family":"Breij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2019.102625_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719849496","article-title":"Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia","volume":"10","author":"Guerra","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728214.2016.1257606","article-title":"Emerging biological therapies to treat acute lymphoblastic leukemia","volume":"22","author":"Huguet","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ebiom.2019.102625_bib0003","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/14712598.2014.922535","article-title":"Obinutuzumab for B-cell malignancies","volume":"14","author":"Owen","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ebiom.2019.102625_bib0004","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2008.001024","article-title":"CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-Chop failure","volume":"94","author":"Johnson","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.ebiom.2019.102625_bib0006","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0007","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebiom.2019.102625_bib0008","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1038\/nprot.2014.169","article-title":"Controlled Fab-arm exchange for the generation of stable bispecific IgG1","volume":"9","author":"Labrijn","year":"2014","journal-title":"Nat Protoc"},{"key":"10.1016\/j.ebiom.2019.102625_bib0009","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4161\/mabs.26233","article-title":"Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches","volume":"5","author":"Gramer","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.ebiom.2019.102625_bib0010","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.102625_bib0011","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ymeth.2013.07.018","article-title":"A simple, robust and highly efficient transient expression system for producing antibodies","volume":"65","author":"Vink","year":"2014","journal-title":"Methods"},{"key":"10.1016\/j.ebiom.2019.102625_bib0013","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.7973652","article-title":"Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody","volume":"266","author":"Burton","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2019.102625_bib0014","first-page":"45","article-title":"Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells","volume":"7","author":"Rodrigues","year":"1992","journal-title":"Int J Cancer Suppl"},{"key":"10.1016\/j.ebiom.2019.102625_bib0015","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.4049\/jimmunol.1003926","article-title":"Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition","volume":"187","author":"Overdijk","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ebiom.2019.102625_bib0017","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.ebiom.2019.102625_bib0018","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0019","doi-asserted-by":"crossref","first-page":"13224","DOI":"10.1073\/pnas.1101398108","article-title":"Functional CD47\/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo","volume":"108","author":"Legrand","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebiom.2019.102625_bib0020","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/s41598-017-02823-9","article-title":"Efficient generation of bispecific murine antibodies for pre-clinical investigations in syngeneic rodent models","volume":"7","author":"Labrijn","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2019.102625_bib0021","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.173.6.1483","article-title":"The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region","volume":"173","author":"Canfield","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.ebiom.2019.102625_bib0022","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/332738a0","article-title":"The binding site for C1q on IgG","volume":"332","author":"Duncan","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2019.102625_bib0023","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/332563a0","article-title":"Localization of the binding site for the human high-affinity Fc receptor on IgG","volume":"332","author":"Duncan","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2019.102625_bib0024","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","article-title":"Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc","volume":"164","author":"Idusogie","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0025","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1107\/S0907444908007877","article-title":"Structural characterization of a human Fc fragment engineered for lack of effector functions","volume":"64","author":"Oganesyan","year":"2008","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ebiom.2019.102625_bib0026","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ebiom.2019.102625_bib0027","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.4049\/jimmunol.143.8.2595","article-title":"Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region","volume":"143","author":"Tao","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0028","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/j.1460-2075.1985.tb03634.x","article-title":"The T3\/T cell receptor complex: antigenic distinction between the two 20-kd T3 (T3-delta and T3-epsilon) subunits","volume":"4","author":"Pessano","year":"1985","journal-title":"EMBO J"},{"key":"10.1016\/j.ebiom.2019.102625_bib0029","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0030","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V99.9.3256","article-title":"Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure","volume":"99","author":"Polyak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.102625_bib0031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2012.11.007","article-title":"A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and of atumumab","volume":"388","author":"Engelberts","year":"2013","journal-title":"J Immunol Method"},{"key":"10.1016\/j.ebiom.2019.102625_bib0032","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.4049\/jimmunol.158.8.3965","article-title":"Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity","volume":"158","author":"Mack","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0033","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2004-03-0859","article-title":"Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells","volume":"104","author":"Grossman","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.102625_bib0034","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","article-title":"Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia","volume":"13","author":"Friedrich","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ebiom.2019.102625_bib0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1267891","article-title":"Overcoming resistance to HER2-targeted therapy with a novel HER2\/CD3 bispecific antibody","volume":"6","author":"Lopez-Albaitero","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ebiom.2019.102625_bib0036","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.4161\/19420862.2014.975660","article-title":"CEA\/CD3 bispecific antibody MEDI-565\/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas","volume":"6","author":"Oberst","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.ebiom.2019.102625_bib0037","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/2326-6066.CIR-14-0230-T","article-title":"Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody","volume":"3","author":"Xu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ebiom.2019.102625_bib0038","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.4049\/jimmunol.139.11.3802","article-title":"Activated lymphocytes during acute Epstein-Barr virus infection","volume":"139","author":"Tomkinson","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2019.102625_bib0039","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1172\/JCI43437","article-title":"MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors","volume":"120","author":"Leisegang","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2019.102625_bib0040","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00262-010-0844-y","article-title":"Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTe antibodies specific for a large melanoma surface antigen","volume":"59","author":"Bluemel","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ebiom.2019.102625_bib0041","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-Proximal epitope facilitates efficient T cell synapse formation by Anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ebiom.2019.102625_bib0042","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.102625_bib0043","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/(SICI)1097-0215(19990209)80:4<612::AID-IJC21>3.0.CO;2-K","article-title":"Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study","volume":"80","author":"Pfosser","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ebiom.2019.102625_bib0044","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1073\/pnas.1014515107","article-title":"FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo","volume":"107","author":"Nimmerjahn","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebiom.2019.102625_bib0045","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/annonc\/mdx150","article-title":"(Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL)","volume":"28","author":"Friberg","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ebiom.2019.102625_bib0046","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov."}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419308400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419308400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:56:12Z","timestamp":1762455372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419308400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":46,"alternative-id":["S2352396419308400"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.102625","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.102625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102625"}}